Healthcare cost trends are increasing to levels not seen in over a decade. Learn what you can do to help mitigate benefits costs.
Trend is a forecast of per capita claim cost increases that take into account various factors, including price inflation, utilization, government-mandated benefits, and new treatments, therapies and technology. Trend is the estimated increase in future healthcare costs.
Although there may be a high correlation between a trend and the actual cost increase assessed at renewal, trend and the net annual change in plan costs are not necessarily the same.
Other factors that impact renewals include, but are not limited to:
Click here to learn more about healthcare trends vs renewals.
Price inflation could be impacted by:
Rising hospital prices remain a significant cost driver. Many hospitals are facing narrow profit margins due to various factors such as labor costs, recovering from the pandemic, inflation, advancements in technology and legislative reforms. Price disparities vary significantly by market, with studies suggesting that consolidation leads to increased costs with minimal differences in quality.
Click here to learn about the impacts of COVID-19 on the health care system.
The second major driver of medical plan cost trends is the rising prices of physician services. This increase is primarily driven by inflation, higher negotiated contract renewal rates and consolidation activities, such as mergers between physician groups, vertical consolidation and private equity acquisitions of physician practices. The pandemic-induced economic challenges and inflation have also contributed to these increased rates.
When analyzing trends, high-cost claimants are a significant factor driving rising prices. Understanding the potential impact of high-cost events, including their increased frequency, is crucial for assessing a plan's overall experience. Several factors contribute to high-cost events, including an aging population, the increasing prevalence of chronic conditions and the introduction of expensive new treatments, especially gene therapies. Gene therapy entrants into the marketplace have increased by an order of magnitude from two in 2021 to an expected 20 in 2024 with an additional 50% forecasted growth over the next three years. The average cost of gene therapies ranges from $2.4M to $3.4M per claimant.
While the high utilization of telehealth services experienced during the peak of the pandemic has decreased, it continues to result in a net increase in acute care visits and mental health services for most plans. According to SHAPE data, there was a 25% increase in emergency room visits related to suicide from 2018 to 2022. Mental health comorbidity has become increasingly common among high-cost participants.
Click here to learn more about the impacts of telehealth and mental health services
TriNet Resources:
High-cost specialty Rx utilization continues to expand as new specialty therapies enter the market and the average cost per day’s supply for specialty Rx is over 50 times greater than the average cost for non-specialty medications. GLP-1s for diabetes and anti-obesity treatments (when allowed by the plan) average over $5,000 per claimant per year. Additionally, public health stockpiling for COVID-19 treatment has wound down: previously, cost for COVID-19 antivirals was paid for by the federal government. Average wholesale price for Paxlovid is now over $1,600 per course.
Click here to learn more about the rising costs of GLP-1s.
Health navigators and health advocate services have exceeded the requirements of transparency regulations by assisting participants in maximizing their healthcare benefits. These patient advocacy services typically involve identifying high-quality providers, offering personalized health recommendations, guiding participants to preferred provider options and sometimes assisting with appointment scheduling.
TriNet Resources:
Wellness programs promote healthy behaviors among employees, such as regular exercise, healthy eating and preventive screenings. By detecting health issues early or preventing them altogether, people are less likely to require costly medical treatments.
TriNet Resources:
There are cost savings when mail order programs are used to fill scripts vs. using retail pharmacies.
TriNet Resources:
Most specialty drugs are biologics derived from viruses or living organisms; biosimilars are "highly similar” to existing biologic medications (akin to generic versions of traditional non-specialty brand drugs) and represent potential savings over the unit cost for existing brand-name specialty Rx. Early indicators for Humira biosimilars reveal unit cost savings and increased adoption in 2024. Formulary management to incent or restrict use to biosimilars when available helps control specialty pharmacy costs. Increased introduction of biosimilars for other blockbuster specialty drugs (Stelara, Simponi, etc.) likely over the next few years as biosimilar manufacturers work through FDA approvals alongside brand-name patent challenges.
Click here to learn ways to potentially reduce health care cost through behavior change.
*2024 Segal Health Plan Trend Survey